Page last updated: 2024-09-03

celastrol and lapatinib

celastrol has been researched along with lapatinib in 1 studies

Compound Research Comparison

Studies
(celastrol)
Trials
(celastrol)
Recent Studies (post-2010)
(celastrol)
Studies
(lapatinib)
Trials
(lapatinib)
Recent Studies (post-2010) (lapatinib)
88517411,9193051,442

Protein Interaction Comparison

ProteinTaxonomycelastrol (IC50)lapatinib (IC50)
Bile salt export pumpHomo sapiens (human)7.375
Epidermal growth factor receptorHomo sapiens (human)0.0827
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.0537
Platelet-derived growth factor receptor betaHomo sapiens (human)8.5
D(1A) dopamine receptorSus scrofa (pig)0.06
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)1
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)0.1659
Alpha-1A adrenergic receptor Sus scrofa (pig)0.06
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)3.2

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bailey, TA; Band, H; Band, V; Clubb, RJ; Duan, L; Natarajan, A; Nyong, AM; Ortega-Cava, C; Raja, SM; Reddi, AL; Williams, SH; Zhao, X1

Other Studies

1 other study(ies) available for celastrol and lapatinib

ArticleYear
Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
    Cancer biology & therapy, 2011, Jan-15, Volume: 11, Issue:2

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lapatinib; Mice; Mice, SCID; Pentacyclic Triterpenes; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Triterpenes; Tumor Burden; Xenograft Model Antitumor Assays

2011